When a high white-cell count refuses to explain itself
Leukocytosis is easy to recognize but sometimes remarkably difficult to explain.
A patient may repeatedly present with an elevated white blood cell count, fever, fatigue, weight loss, night sweats, pain or other systemic symptoms. Antibiotics may have been prescribed. Imaging may be inconclusive. Cultures may remain negative. Routine investigations may fail to identify a clear source. Yet the leukocyte count continues to rise—or remains persistently abnormal.
This is where clinicians must move beyond simply asking, “What is the WBC count?”
The more important questions are:
Why is it elevated? Is the elevation reactive or clonal? Is there an occult infection? Is tuberculosis hiding outside the lungs? Could there be an invasive fungal infection? Could inflammation, medication, malignancy or an immune disorder be responsible? And, most importantly, what diagnosis can explain the entire clinical picture?
For the purposes of this clinical discussion, the term *CRESLUO—Chronic Refractory Symptomatic Leukocytosis of Unknown Origin—*can be used as a practical descriptive framework for such difficult cases. It should not be confused with a formally established disease diagnosis.
The approach requires patience, pattern recognition and disciplined investigation.
1. First principle: leukocytosis is a sign, not a diagnosis
Leukocytosis commonly means a WBC count above approximately 11,000/mm³ in a non-pregnant adult, but the significance depends on the differential count, duration, clinical context and associated laboratory abnormalities.
The differential diagnosis is broad.
Major causes include:
- Infection
- Bacterial infections
- Tuberculosis
- Viral infections
- Parasitic infections
- Deep-seated abscesses
- Endocarditis
- Occult urinary, abdominal or hepatobiliary infection
- Opportunistic infections
- Invasive fungal infections
- Hematological disorders
- Acute leukemia
- Chronic myeloid leukemia
- Other myeloproliferative neoplasms
- Lymphoid malignancies
- Leukemoid reactions
- Chronic inflammatory disease
- Autoimmune disease
- Vasculitis
- Inflammatory bowel disease
- Granulomatous disorders
- Chronic tissue inflammation
- Drugs and physiological stress
- Corticosteroids
- Beta-agonists
- Lithium
- Epinephrine
- Colony-stimulating factors
- Severe physiological stress
- Other causes
- Smoking
- Obesity
- Asplenia
- Tissue injury
- Hemolysis
- Recovery from bone-marrow suppression
A systematic evaluation is therefore essential. The duration of leukocytosis itself is an important clue: an abnormality lasting months has a very different differential from an acute elevation occurring over hours or days. (AAFP)
2. The first diagnostic fork: reactive or clonal?
The first major question is:
“Is the bone marrow reacting to something—or is the marrow itself diseased?”
A careful history and examination should be followed by:
- Repeat CBC with differential
- Peripheral blood smear
- Hemoglobin and platelet count
- ESR and CRP
- Renal and liver function
- LDH
- Relevant cultures
- Medication review
- Imaging directed by symptoms
- Assessment for lymphadenopathy and splenomegaly
The peripheral smear can provide crucial information about immature cells, blasts, toxic changes, left shift and other clues.
Marked leukocytosis, particularly very high counts, should trigger urgent consideration of hematological malignancy. A WBC count above 100,000/mm³ is particularly concerning for leukemia or a myeloproliferative disorder. (AAFP)
Depending upon the findings, hematological evaluation may require:
- Flow cytometry
- Molecular testing
- Bone-marrow aspiration/biopsy
- Cytogenetic studies
- Disease-specific molecular markers
Never allow the label “infection” to become a substitute for excluding leukemia or another clonal disorder.
3. The second question: where is the hidden infection?
Once an obvious hematological cause has not been demonstrated, the clinician must reconsider infection.
This is where the clinical detective work becomes important.
An occult infection may be present in:
- Lung
- Liver
- Gallbladder
- Kidney
- Urinary tract
- Abdomen
- Bone
- Spine
- Lymph nodes
- Heart valves
- Brain
- Skin and soft tissue
- Deep pelvic or retroperitoneal spaces
A patient may not always have classic symptoms.
For example, tuberculosis can involve lymph nodes, pleura, abdomen, bones, joints, meninges and other organs. Extrapulmonary TB is particularly challenging because it may be paucibacillary and can mimic other diseases. WHO emphasizes obtaining specimens from suspected sites for appropriate molecular testing, culture and/or histopathology whenever possible. (TB Knowledge Sharing)
This is why a “normal chest X-ray” does not automatically eliminate tuberculosis from the differential diagnosis.
4. Tuberculosis: when should empirical ATT enter the discussion?
In regions where tuberculosis is prevalent, TB deserves serious consideration in an unexplained inflammatory syndrome—but leukocytosis alone should never be used as justification for empirical anti-tubercular therapy (ATT).
The correct question is:
“Does this patient have a sufficiently convincing clinical, radiological, epidemiological or pathological picture of tuberculosis?”
Clues may include:
- Prolonged fever
- Night sweats
- Unexplained weight loss
- Chronic cough
- Lymphadenopathy
- Pleural or pericardial disease
- Unexplained abdominal disease
- Spinal or osteoarticular lesions
- CNS manifestations
- Relevant exposure history
- Immunosuppression
- Imaging compatible with TB
- Tissue granulomatous inflammation
- Positive molecular testing or culture
Modern TB practice strongly emphasizes rapid molecular diagnostics and microbiological confirmation whenever feasible. WHO notes that bacteriological confirmation is important because it also permits assessment of drug resistance. (World Health Organization)
But what about empirical ATT?
There are circumstances in which treatment may need to begin before microbiological confirmation—particularly when a patient is seriously ill or deteriorating and the clinical probability of TB is high.
WHO describes empirical treatment as particularly relevant in selected seriously ill patients in whom establishing the diagnosis rapidly is difficult. However, every effort should still be made to obtain diagnostic confirmation and reassess the diagnosis as results become available. (TB Knowledge Sharing)
Therefore:
Empirical ATT is a calculated clinical decision—not a blind therapeutic trial for unexplained leukocytosis.
If empirical treatment is started, the clinician should establish a baseline, define the expected response, monitor toxicity and continuously reconsider alternative diagnoses.
5. The fungal question: could an invasive fungal infection be hiding?
The second major infectious blind spot is fungal disease.
Invasive fungal infections are particularly important in patients with:
- Prolonged neutropenia
- Hematological malignancy
- Chemotherapy
- Transplantation
- Prolonged ICU admission
- Major abdominal surgery
- Central venous catheters
- Prolonged broad-spectrum antibiotic exposure
- Corticosteroid or other immunosuppressive exposure
- Severe critical illness
Importantly, antifungal therapy should not be started merely because leukocytosis persists.
For example, IDSA recommendations support empiric antifungal treatment in selected high-risk patients with persistent fever and prolonged neutropenia despite appropriate antibacterial therapy, while biomarker-driven or pre-emptive strategies may reduce unnecessary antifungal exposure in suitable settings. (Infectious Diseases Society of America)
For suspected invasive candidiasis in critically ill patients, empiric therapy may be considered when significant risk factors are present and no other cause explains the illness; however, the potential benefit must be balanced against toxicity, cost and antifungal resistance. (Infectious Diseases Society of America)
The principle is simple:
Treat the patient who has a credible fungal-risk profile—not the laboratory number alone.
6. Why “empirical treatment” can become dangerous
Empirical therapy can sometimes be lifesaving.
But empirical therapy without a diagnostic strategy can also become a trap.
Unnecessary ATT can expose patients to:
- Hepatotoxicity
- Drug interactions
- Neurological adverse effects
- Other drug-specific toxicities
- Financial burden
- Diagnostic delay
Unnecessary antifungal therapy may produce:
- Hepatic toxicity
- Renal toxicity
- Drug interactions
- QT-related effects with selected agents
- Selection of resistant organisms
- Substantial treatment cost
Perhaps the biggest danger is psychological:
“The patient is already receiving treatment, so perhaps we do not need to search further.”
That mindset can delay the diagnosis of leukemia, lymphoma, autoimmune disease, inflammatory disorders or an occult bacterial infection.
7. Prof. (Dr.) Rohit Chhirolya’s cost-conscious diagnostic philosophy
A cost-effective medical approach does not mean ordering fewer investigations indiscriminately.
It means ordering the right investigation at the right time.
The practical philosophy can be summarized as:
HISTORY → EXAMINATION → BASIC TESTS → PATTERN RECOGNITION → TARGETED TESTS → EARLY SPECIALIST INPUT → REASSESSMENT
Instead of immediately ordering every available investigation, the clinician can construct a probability-based diagnostic pathway.
For example:
Step 1: Confirm that leukocytosis is persistent.
Step 2: Identify the predominant cell line—neutrophilic, lymphocytic, eosinophilic or mixed.
Step 3: Review the peripheral smear.
Step 4: Search systematically for infection, inflammation, medication-related causes and malignancy.
Step 5: Use imaging according to the clinical findings rather than in indiscriminately.
Step 6: If TB is genuinely suspected, obtain appropriate samples for molecular testing, culture and histopathology whenever feasible.
Step 7: If invasive fungal infection is plausible, assess host risk factors and use appropriate cultures, imaging and fungal biomarkers where indicated.
Step 8: If the pattern remains unexplained, escalate early to hematology, infectious disease, rheumatology or other relevant specialties.
Step 9: Reassess the entire diagnosis if the patient does not respond as expected.
This approach can potentially prevent the expensive cycle of repeated nonspecific tests, unnecessary medications and delayed definitive diagnosis.
8. Early diagnosis is itself a treatment strategy
One of the most important lessons from difficult leukocytosis cases is that time has diagnostic value.
A WBC count that remains abnormal for weeks or months gives the clinician an opportunity to compare:
- Previous CBCs
- Differential counts
- ESR/CRP trends
- Imaging progression
- Weight trajectory
- Fever pattern
- Response to antibiotics
- Medication exposure
- New organ involvement
The trend can sometimes be more informative than a single laboratory value.
The goal is not simply to reduce the WBC count.
The goal is to discover why it is high.
A falling WBC count after treatment may be reassuring—but it does not automatically prove that the presumed infection was the cause.
Similarly, failure to respond to empirical therapy should not simply trigger another empirical drug.
It should trigger diagnostic reconsideration.
9. The “mind-igniting” question
In every chronic refractory case, ask:
“What diagnosis am I assuming—and what diagnosis am I failing to consider?”
That single question can change clinical reasoning.
If tuberculosis is being assumed, ask:
Where is the evidence?
If fungal infection is being assumed, ask:
What is the host-risk profile?
If bacterial infection is being assumed, ask:
Where is the source?
If malignancy is being assumed, ask:
What does the smear, marrow or molecular evaluation show?
If inflammation is being assumed, ask:
Which inflammatory disease fits the entire phenotype?
This is the essence of disciplined clinical medicine.
Conclusion
Chronic Refractory Symptomatic Leukocytosis of Unknown Origin—or CRESLUO, as a practical descriptive term—represents a diagnostic challenge rather than a single disease.
The clinician must simultaneously keep infection, tuberculosis, invasive fungal disease, inflammatory disorders, medication effects and hematological malignancy in the differential diagnosis.
Empirical anti-tubercular therapy has a role only when the clinical probability and severity justify it, while every reasonable effort should be made to establish microbiological or pathological evidence. Similarly, empirical antifungal therapy should be reserved for appropriately selected high-risk situations rather than unexplained leukocytosis alone. (TB Knowledge Sharing)
The most cost-effective approach is therefore not simply “fewer tests.”
It is:
EARLY RECOGNITION + SMART TEST SELECTION + TARGETED EMPIRICAL THERAPY WHEN JUSTIFIED + CONTINUOUS DIAGNOSTIC REASSESSMENT
That is where clinical experience matters.
A persistent abnormal laboratory value should never become the diagnosis itself.
Find the disease behind the number.
Educational note: This article is intended for medical education and does not replace individualized assessment. Anti-tubercular or antifungal medicines should not be started, stopped or modified without appropriate medical evaluation and monitoring.
Take the First Step Toward Better Neurological Health:
- Call 7985022365 for appointments
- Schedule Consultation: Nilakantha Brain Clinic
Stay Connected for Brain Health Updates:
- Latest research: Facebook
